Humira®
GoodRxAdalimumab · subcutaneous injection
Misc., Injections & Implants
Approved uses
Non-infectious intermediate, posterior and panuveitis, adults
80 mg subcutaneously once, then 40 mg every other week starting one week later
The reason an optometrist opens this card; the rest of its label is rheumatology
Non-infectious uveitis, children aged 2 and over
10 mg every other week at 10 to under 15 kg; 20 mg every other week at 15 to under 30 kg; 40 mg every other week at 30 kg and above
Contraindications
None.
Available FormsInjection, pre-filled pen and syringe delivering 10 mg, 20 mg, 40 mg or 80 mg of adalimumab subcutaneously.
Mechanism of ActionAdalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques.
Warnings & Precautions
- Serious infections, including tuberculosis, invasive fungal infection and bacterial sepsis, have led to hospitalization and death; test for latent tuberculosis before starting. This carries a boxed warning.
- Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF blockers. This carries a boxed warning.
- Demyelinating disease, including optic neuritis, has been reported.
- Heart failure may worsen or newly appear.
- Hepatitis B may reactivate in carriers.
Common Side Effects
The most common adverse reaction with HUMIRA was injection site reactions.
Pregnancy & LactationPregnancy: Available data do not indicate a drug-associated risk of major birth defects; adalimumab crosses the placenta and can be detected in the infant for months after birth, which matters for live-vaccine timing.
Lactation: Adalimumab is present in human milk at low levels; absorption by the infant is unlikely.
Pediatric UseThe safety and effectiveness of HUMIRA have not been established in pediatric patients with psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis.